Every article, report, and earnings note where SDGR appears.
Nanyang Biologics is an AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers exposure to a preclinical platform at a $1.5 billion headline value, but shareholders should watch redemptions, dilution, and whether the deal closes with enough cash.
GNQ Insilico is a TechBio and precision-medicine company going public through a merger with IB Acquisition Corp. (Nasdaq: IBAC), with the deal originally expected to close in Q3 2026. The bull case is an AI-driven drug discovery platform; the bear case is a small trust, heavy financing dependence, and meaningful dilution risk.
This countdown spans AI-native drug discovery, computational chemistry, genomics, diagnostics, antibody platforms and data-rich biotech businesses.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate SDGR ReportCancel anytime